Member Info for ShearClass

UK ramping won't make any difference, the share price is inextricably tied to Euronext Paris - volume there so far today is just 19k shares, but the price is down to €3.908. On LSE there were buys of 7375 & 14716 & total volume of 61k, but zero impact on the price. Same old same old...

No idea what you're talking about 1bb?! Seems like a sensible post to me, hence why it's got 10 upticks...

Yeah its 1000% not a rumour, it's from the guy running the ACTIV trial! He also talked about SNG in Jan before we got the RNS, so has form.

I suspect that the strategic plan will involve a deslisting from Euronext as this will simplify corporate matters & quite honestly there is no reason for us to remain listed over there. Whether we get this in Q2 is up for debate, it would certainly be nice but not the end of the world if it take a little longer.

I also wouldn't be surprised in the slightest if a takeover bid arrived out of the blue, if Danish private equity have decided that BBI are worth £500m then I think it's a given we'll have received informal approaches, although the DHSC dispute may have disrupted things.

"Diagnostics is a very attractive space which, with an enhanced global focus on preventative medicine, will play an increasingly important part in improving health outcomes for patients around the world. We see tremendous opportunities for both organic and inorganic growth for the company."

Clearly the above applies to NCYT...

https://www.prnewswire.com/news-releases/novo-holdings-acquires-bbi-group-301312183.html

"COPENHAGEN, Denmark, June 15, 2021 /PRNewswire/ -- Novo Holdings A/S, a leading global life sciences investor, today announced it has acquired BBI Group ("BBI"), a leading supplier of products and services to the global diagnostics and life sciences industries, from Exponent for an enterprise value of over GBP 400 million."

As per companies house, they had £125m of bank loans outstanding at the end of 2019. So the equity valuation is likely to be over £500m. Their turnover was £57m for YE 2019 (a decrease on the prior year), though annoyingly no accounts for 2020 at present. We know they are part of the UK-RTC alongside ODX, and know they haven't received any material orders yet (i.e. on Bidstats or the DHSC >25k releases), so it's hard to imagine their 2020 turnover reached anything more than £100m.

Our valuation is the definition of madness.

Yep. Funds will only be able to ignore AWE on a pretentious 'valuation basis' for so long... the post IPO dark period ends on 21st June, so we'll get broker research & forecasts, that should help a few make up their minds.

It’s gradually decreasing to reflect the lack of positive news since IPO. 3 months in and the only material news is that the CFO is leaving. I wouldn’t be surprised to see it head back towards the 175p IPO price unless they step up the PR

Great stuff Wilson, I read the second half of the page after posting the first half on here, I hadn't tied it to the comments made by GM about inclusion in lighthouse labs... the evidence is compelling and this will surely boost our chances of landing international contracts dramatically.

IMO this is more exciting than the forthcoming LFT, as if we are leading the way for variant detection in the UK & the UK is considered to be the world leader in variant analysis then we appear to have a genuine competitive advantage (speed of target validation), and certainly a first mover advantage for variants.

Thanks Kaeren, did look through but there has been a lot of posts today! Very interesting indeed, especially when you consider GM said last week; "we believe our SNPsig® portfolio is the world's largest for detecting SARS-CoV-2 variants."

Did anyone ever find details of the NHS VoC framwork by the way?

Pretty sure that this hasn't been posted yet as it was only released this morning by PHE...

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/992989/AB1_Variants_of_Concern_VOC_Technical_Briefing.pdf

Potentially very exciting confirmation that EscapePLEX / SNPsig is being used by PHE for rapid genotyping to track to the spread of Delta on P9;

"Technical Briefing 15 includes variant diagnoses made both by whole-genome sequencing and by a genotyping PCR test. Genotyping allows shorter turnaround time (12-24h after initial confirmation of COVID-19) for a probable variant result. The initial panel of targets began trials in March 2021, using single nucleotide polymorphisms (SNPs): N501Y, E484K, K417N and K417T. Results have been reported and used for public health action since 29 March 2021. On 11 May 2021, after rapid validation of targets to allow identification of Delta variant, P681R was introduced in the panel to replace N501Y. Genotyping results have now been fully integrated into the Variant data reports and analyses."

It ties in perfectly with the RNS from last week, especially re. detection of the P681R gene...

Let's wait and see. I'm not sure why I'm even bothering to post here as until we get clarity there will always be doubters 7 to be honest this BB has become toxic. I'll be back on 29th June and we will see who has called this correctly.

The purpose of my post was to illustrate how idiotic your statement was. I've no intention of convincing anyone to buy shares, especially not someone that is very likely short of the shares but definitely short of brain cells.

"I think you all make dangerous assumptions about the amount of cash being held"

Macmdude. Have you actually tried to do the maths to prove this? (That's a rhetorical question, as clearly you haven't).

They had €19.8m at 30/06/2020. This is a fact.

Second half prior to the DHSC contract was on course to exceed the first half (EBITDA profitability of >€100m).

First half generated cash of €40m. Margins for H2 were anticipated to be the same as H1, so cash generation would be similar. Let's be prudent and say €35m.

We also had €28m of receivables at 30/06, €14m of inventory & €16m payables. A net asset value of €26m.

So completely ignoring DHSC, year end cash would have been between €54 - €80m.

We've then delivered around £35m of private / non DHSC sales in Q1, likely generating another £20m or so.

So ignoring the £185m of DHSC revenue which has been flagged to the market, cash + receivables at the end of Q1 would have been between €75-100m.

The funniest thing is that we also already know that DHSC has paid us a further £40m ex VAT in February, to add to the £104 ex VAT that they paid us in October + November!

And to add further support, the company confirmed it's cash balances were £91.8m at 31/12/20. This is a fact.

So please, give us any shred of evidence as to why we are making 'dangerous assumptions' about the cash balances?

Looks like the price has been brought down to the £6 region to allow some institutional holders to exchange shares - 5th highest volume of all time (since 2012) and it's only 10.30am. Once done I suspect it'll ping back to £7ish, an EBITDA miss of £10m does not warrant a 25% fall...

They sold shares exactly 1 year after they bought them in the placing @ £1.20, so this would appear to be a lock in expiring or something similar.

Got to laugh at Euronext, where someone just decided to sell 40k shares in tiny volume at 8p below the price at the time… it’s bizarrely illiquid over there. We’ve got 5% upside just to hit Oddo’s ridiculous €4.10 target now!

The best thing that all of the regular posters can do is filter both VanV & Troublesome, responding to them is simply adding their ego's (ego) and encouraging the white noise to continue / worsen... By responding you are simply encouraging it to continue.

Yeah the test NSCI have agreed to commercialise is a serology test, revenue really hasn't taken off for them yet (RENX + EKF have a world class one which got FDA EUA approval late last year, but no material revenues yet). I'd be surprised if our LFT isn't with either AZN or GSK, we've been working with them since April 2020 and the amount of combined knowledge accrued to date must be huge. I'm expecting something major for GM to use the phrase 'significant revenues'...

Considering the email was also corroborated this morning by Larry, I have zero reason to doubt it's authenticity. It makes sense to have a standard response like that for PI questions as it's far better to respond with something relatively generic that to not respond at all!

Old news - unless Sir Geoffrey Adams is in the habit of repeating what he said in 2020 ad verbatim.

Re. dozy Graham @Oriens1,the funny thing is if they had RNS’d this and the share price stayed flat you’d have been criticising GM for the wording of the announcement or why they hadn’t disclosed the financials.

Damned if they do and damned if they don’t!